Article Text

Download PDFPDF
Adult nursing
Bridging anticoagulation therapy with low molecular weight heparin in patients with atrial fibrillation following a stroke is associated with adverse events
  1. Rachel Kennedy
  1. Cardiology Department, University Hospital Limerick, Dooradoyle, Ireland
  1. Correspondence to Rachel Kennedy, Cardiology Department, University Hospital Limerick, Dooradoyle V94 F858, Ireland; rachel.staunton{at}gmail.com

Statistics from Altmetric.com

Commentary on: Altavilla R, Caso V, Bandini F, et al. Anticoagulation after stroke in patients with atrial fibrillation. Stroke 2019;508:2093–100.

Implications for practice and research

  • Healthcare professionals need to be aware that bridging anticoagulation therapy with low molecular weight heparin (LMWH) in patients with atrial fibrillation following a stroke is associated with a higher rate of recurrent ischaemic and haemorrhagic events compared with patients who do not receive bridging therapy.

  • Strategies to ensure adherence to the guidelines need to be devised and implemented within the clinical setting.

Context

Patients with cardioembolic stroke and non-valvular atrial fibrillation are at a high risk of early stroke recurrence.1 Oral anticoagulation therapy (OAC) in the form of vitamin K antagonists (VKAs) and non–vitamin-K oral anticoagulants (NOACs) are the medical therapy of choice in the secondary prevention of …

View Full Text

Footnotes

  • Twitter @RachyKennedy

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.